Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Nov 2016
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 25 Mar 2013 Planned end date changed from 1 Feb 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 25 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Jul 2011 Planned End Date changed from 1 Nov 2013 to 1 Feb 2013 as reported by ClinicalTrials.gov.